New weight-loss shot appears to outperform other obesity drugs on market

Eli Lilly says participants in a sizable trial of retatrutide lost much more weight compared to other weight-loss drugs

A new weight-loss drug has helped participants in a sizable trial lose much more weight than other obesity drugs already on the market – up to an average of 28% of their body weight – Eli Lilly announced Thursday.

The Indiana-based pharmaceutical company in a press statement said that retatrutide, a once-weekly triple hormone receptor agonist, led to an average weight loss of 70.3lbs (28.3%) over 80 weeks among participants receiving the 12mg dose, with 45.3% achieving at least 30% weight loss.